MOTS-c Dosage Chart

Overview

MOTS-c is a mitochondrial-derived peptide discussed in wellness, performance, and metabolic-health circles, but it does not have an FDA-approved dose or a universally accepted clinical protocol. This guide explains how people commonly read a MOTS-c dosage chart, what a "mots c 10mg" vial means, and why any MOTS-c dosing decision should be handled with a qualified medical professional rather than copied from the internet. You can use our MOTS-c dosage calculator → to check concentration and dose-volume math after your clinician has confirmed the details.

MOTS-c dosage chart in text format

The following MOTS-c dosage chart is presented in text format for educational discussion only. It summarizes commonly referenced ranges seen in peptide-clinic and research-oriented conversations, while clearly separating them from an approved medical dose. Do not use this as a self-treatment plan; a clinician should evaluate health history, medications, goals, labs, and risk factors before any MOTS-c dosage protocol is considered. If you want to cross-check reconstitution math, use our MOTS-c dosage calculator → — but only for concentration calculations, never for self-dosing.

Level	Amount	Frequency	Duration	Key Notes
Cautious exploratory	2.5 mg	1-2x weekly	4-6 weeks	Conservative starting point under supervision. Monitor tolerability, injection-site reactions, energy, sleep, appetite, glucose.
Moderate intermittent	5 mg	2-3x weekly	4-8 weeks	Commonly discussed range. Extra caution with diabetes, cardiovascular disease, pregnancy, autoimmune conditions.
Higher-frequency metabolic	5 mg	3-5x weekly	4-12 weeks	Sometimes framed around metabolic support or training blocks. "Commonly discussed" does not mean clinically validated.
10 mg administration	10 mg	1-3x weekly	4-8 weeks	"Mots c 10mg" may refer to total vial content, not per-injection dose. Do not inject the whole vial unless prescribed.
Investigational clinical-trial	Fixed dose (not public)	Daily	12 weeks	Phase 2a study with safety follow-up through Week 16. Not a public dosing recommendation. (clinicaltrials.gov)

Reference level 1: cautious exploratory discussion

• Amount: 2.5 mg per administration
• Frequency: 1-2 times weekly
• Typical duration discussed: 4-6 weeks
• Relevant notes: This lower-end mots c dose is sometimes discussed for people who are sensitive to new compounds or who want a conservative starting point under supervision. It is not an official starting dose. Monitoring would generally focus on tolerability, injection-site reactions, energy changes, sleep, appetite, glucose patterns if relevant, and any unusual symptoms.

Reference level 2: moderate intermittent schedule

• Amount: 5 mg per administration
• Frequency: 2-3 times weekly
• Typical duration discussed: 4-8 weeks
• Relevant notes: This is one of the more commonly discussed MOTS-c dosing ranges online. The practical idea is intermittent exposure rather than daily use, but the best frequency has not been established in large human dose-ranging trials. Anyone with diabetes, prediabetes, cardiovascular disease, kidney disease, liver disease, autoimmune conditions, pregnancy, or active medication changes should be especially cautious and medically supervised.

Reference level 3: higher-frequency metabolic cycle

• Amount: 5 mg per administration
• Frequency: 3-5 times weekly
• Typical duration discussed: 4-12 weeks
• Relevant notes: This type of mots-c dosage protocol is sometimes framed around metabolic support, training blocks, or body-composition goals. The key limitation is that "commonly discussed" does not mean clinically validated. More frequent administration increases the importance of tracking adverse effects and avoiding stack-heavy protocols where it becomes impossible to identify what caused a response.

Reference level 4: 10 mg administration discussion

• Amount: 10 mg per administration
• Frequency: Often discussed as 1-3 times weekly, depending on the protocol source
• Typical duration discussed: Short cycles such as 4-8 weeks
• Relevant notes: Searches for "mots c 10mg" can be confusing because 10 mg may refer to the total amount in a vial, not necessarily the intended amount per injection. A vial labeled 10 mg contains 10 mg total before reconstitution and dose measurement. It should not be interpreted as "inject the whole vial" unless a licensed clinician specifically prescribes and explains that plan.

Reference level 5: investigational clinical-trial model

• Amount: Fixed dose, not publicly detailed in the study summary
• Frequency: Once daily subcutaneous injection
• Typical duration: 12 weeks in the listed Phase 2a study, with safety follow-up through Week 16
• Relevant notes: This is the closest current example of formal human investigation, but it is not a public MOTS-c dosing recommendation. Clinical trials include screening, eligibility criteria, adverse-event monitoring, laboratory review, and defined endpoints that are not replicated by casual self-use. (clinicaltrials.gov)

How should you interpret a mots c 10mg vial?

A mots c 10mg vial usually means the vial contains 10 milligrams of MOTS-c powder before it is mixed with diluent; it does not automatically define the dose, injection volume, schedule, or cycle length. The actual amount delivered depends on reconstitution volume, concentration, syringe markings, and the intended mg per administration. This is one reason dosing errors are common with peptides: people may confuse total vial content, concentration, units on an insulin syringe, and the desired MOTS-c dose.

For example, if a clinician-approved plan calls for a 5 mg administration from a 10 mg vial, that would represent half the total vial content after proper reconstitution. If the plan calls for 2.5 mg, that would represent one quarter of the vial content. The exact injection volume cannot be known from "10 mg" alone because it depends entirely on how much diluent is added. A MOTS-c dosage calculator → can help with this concentration math, but it cannot determine whether a dose is medically appropriate.

A safer interpretation checklist looks like this:

• Confirm whether "10 mg" refers to vial content or a planned per-dose amount.
• Confirm the reconstitution volume in milliliters.
• Calculate the final concentration before measuring any dose.
• Use only the syringe type your clinician or pharmacist specifies.
• Label the vial with concentration and date mixed.
• Stop and ask for help if "mg," "mL," and "units" are being used interchangeably.

A practical MOTS-c dosing checklist

Before anyone considers a MOTS-c dosage protocol, the most useful step is not choosing a number from a chart. It is deciding whether the compound is appropriate, legally accessible, and medically sensible for that person. Because MOTS-c is not an approved therapy, quality, sterility, labeling accuracy, and follow-up standards can vary widely outside regulated clinical settings.

Use this checklist as a risk-reduction conversation guide:

1. Clarify the goal. Is the goal energy, exercise tolerance, metabolic markers, body composition, or general wellness? Vague goals make it harder to judge benefit or risk.

2. Review medical history. Blood sugar disorders, cardiovascular conditions, pregnancy, cancer history, autoimmune disease, and organ impairment require extra caution.

3. Review medications and supplements. Stacking MOTS-c with GLP-1 medications, stimulants, thyroid drugs, hormones, or other peptides can complicate side-effect tracking.

4. Set baseline markers. A clinician may consider glucose, HbA1c, lipids, liver enzymes, kidney function, blood pressure, weight, waist measurement, and symptom tracking.

5. Track response in writing. Record date, time, amount, injection site, exercise, sleep, appetite, mood, and adverse effects.

6. Avoid rapid escalation. Increasing dose or frequency before understanding tolerance can raise risk without proving added benefit.

7. Know when to stop. Concerning symptoms, allergic reactions, persistent gastrointestinal issues, palpitations, severe fatigue, unusual mood changes, or glucose instability should prompt medical review.

Competitive athletes should be especially careful. USADA describes MOTS-c as an experimental drug and notes that athletes cannot obtain a therapeutic use exemption for it because there is no approved therapeutic use. The WADA Prohibited List is updated regularly and was in force for 2026 from January 1, 2026, so athletes should verify status through official anti-doping resources before using any peptide. (usada.org)

The safest takeaway on MOTS-c dosage

A useful MOTS-c dosage chart can help you understand the language people use around 2.5 mg, 5 mg, and 10 mg discussions, but it should not be treated as a do-it-yourself plan. The most important facts are simple: there is no FDA-approved MOTS-c dose, no universal mots-c dosage protocol, and no chart that can account for your labs, medications, risk factors, or goals.

If you are considering MOTS-c, bring the chart-style information to a qualified clinician and ask better questions: What is the goal? What evidence supports this approach? What monitoring is needed? What would make us stop? That is a far safer way to use a mots-c dosing chart -- as a conversation tool, not a shortcut. If you need to verify reconstitution math, our MOTS-c dosage calculator → can help with the arithmetic, but the medical decision belongs to a qualified clinician.

Related Peptides

Frequently Asked Questions

Related Guides